Abzena has achieved a significant licensing deal for its site-specific ThioBridge antibody drug conjugate (ADC) linker technology with a large US biotech company. This provides important validation of the proprietary technology and the overall strategy. Our rNPV-based valuation of £130m is largely unchanged as underlying assumptions remain broadly similar.
